featured
-

The genetic 'gray area' of Huntington's disease: what does it all mean?
Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained
-

Dimebon fails in late-stage human HD clinical trial
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
-

Interview: CHDI Management
HDBuzz interviews three top scientists from CHDI, the biggest funder and driver of HD research worldwide
-

Welcome to HDBuzz
Welcome to HDBuzz. Huntington’s disease research news. In plain language. Written by scientists. For the global HD co
-

Is Huntington’s disease twice as common as we thought?
New data suggest there may be twice as many people with HD symptoms as previously thought – and even more at risk




